-
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes.
One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a...
IN THE SPOTLIGHT
-
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with... -
2024 ASCO: Highlights of Lung Cancer Research
Read time: 8 minutes Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving... -
Is Lung Cancer in Young Adults Hereditary?
Read time: 2 minutes The question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer... -
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed... -
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these... -
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation... -
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Read time: 7 minutes It’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of... -
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at... -
EGFR Virtual Meetup
EGFR patients/survivors - Join us the 1st Wednesday of every month to connect with others who share common experiences and build your community.
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment. You can register today for…
Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy
Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC
Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC
AstraZeneca’s Tagrisso gains approval in Canada for NSCLC
New treatment approved by Health Canada for people with lung cancer
Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC
Tagrisso with chemotherapy approved in EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
Tagrisso with chemotherapy approved in EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes
Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes
Osimertinib extends PFS by 3.2 years in LAURA
How Can Patients and Researchers Design Clinical Trials Together?
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials. In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials. Through panelist…
2024 ASCO: Highlights of Lung Cancer Research
2024 ASCO: Highlights of Lung Cancer Research
Read time: 8 minutesThousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 through June 4, 2024. The theme for this year’s conference, “The Art and Science of Cancer Care: From Comfort to Cure,” highlighted the importance of using both our creativity and our scientific…
Is Lung Cancer in Young Adults Hereditary?
Is Lung Cancer in Young Adults Hereditary?
Read time: 2 minutesThe question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer diagnosis is approximately 70 years old, we are now seeing young adults in their 20s and 30s getting lung cancer.We currently suspect lung cancer in young adults may be caused by environmental factors (such as air pollution or chemical exposure), their genetic make-up, or some combination of these factors.We cannot say for…
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed with advanced-stage lung cancer. Research is ongoing to help us develop effective options to treat these patients medically, but little is known about the effects of the diagnosis on their mental, social, and financial health or their family planning. To help us better understand the needs of this growing…
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation. Her involvement with the medical system from these different perspectives inspired her to write her recent book, Fatal to Fearless: 12 Steps to Beating Cancer in a Broken Medical System. You can watch the full 40-minute conversation with Kathy or use the timestamps below to learn more about the topics and advice…
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Read time: 2 minutesIntegrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In the webinar below, Gabriel Lopez, MD, medical director of…
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Read time: 7 minutesIt’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of you who are new to this meeting, it is the largest gathering of laboratory scientists and clinicians in the world—coming together to discuss how to take science from the bench (laboratory) to patients and communities. This year’s meeting was held in sunny San Diego and brought together more than 23,000 attendees. Below…
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her…
Caregivers: Planning the Self-Care Journey
Caregivers: Planning the Self-Care Journey
This webinar explains the phases of the caregiving cycle and offers tips and strategies for meeting the challenges of each phase. The discussion features Michelle Bolden, founder and chief education officer for Call For Caring Inc., a nonprofit organization educating and uplifting family caregivers in Atlanta. Michelle also hosts two podcasts -- "Call For Caring on Purpose" and "The Empowerment Hour." The webinar was recorded on March 7, 2024, as a Facebook Live event. It is hosted…
Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer
Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer
Read time: 4 minutesI just returned from the Cancer Grand Challenges Summit, held March 5–8, 2024 in London, England. Cancer Grand Challenges was launched in 2020 as a collaboration between Cancer Research UK and the National Cancer Institute in the US, whereby they provide $25 million to international, multi-institutional teams working to address some of the most perplexing issues in the cancer field. I am LUNGevity’s representative on Team CANCAN, which is working to understand and treat…
General Virtual Meetup
General Virtual Meetup
For patients/survivors - Join us every Tuesday for this general meetup for those impacted by lung cancer.Register in advance for this meeting:After registering, you will receive a confirmation email containing information about joining the meeting.
Leveraging Genetics to Understand Why Younger Adults Are Developing Lung Cancer
Leveraging Genetics to Understand Why Younger Adults Are Developing Lung Cancer
Read Time: 5 minutesIt’s a mystery that has been baffling researchers: Why do some people develop lung cancer in their 20s or 30s? While we used to think lung cancer was only caused by exposure to tobacco and environmental factors like radon, researchers are starting to learn that the development of lung cancer, particularly in younger adults, could have a hereditary component. LUNGevity partnered with the Lung Cancer Initiative, a leading nonprofit in North Carolina, to support…
FDA Approves New Treatment Option: Osimertinib Plus Chemotherapy for EGFR+ NSCLC
FDA Approves New Treatment Option: Osimertinib Plus Chemotherapy for EGFR+ NSCLC
The US Food and Drug Administration (FDA) approved a new treatment option for people diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.Prior to this approval, treatment with osimertinib alone was the gold-standard targeted therapy for this population. The recent approval offers another option to patients – the combination of osimertinib with chemotherapy. This FDA approval is based on the…
Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer
Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer
Approximately 10%-15% of patients with non-small cell lung cancer have tumors with mutations in the EGFR (epidermal growth factor receptor) gene. EGFR mutations are known to drive cancer growth. Many patients living with EGFR-positive lung cancer benefit from targeted therapies called tyrosine kinase inhibitors (TKIs). TKIs, such as osimertinib, can help patients by specifically blocking the effect of these mutations and reducing tumor growth. However, TKI-treated tumors eventually develop drug…
Fertility Preservation and Cancer
Fertility Preservation and Cancer
Medications and treatments for lung cancer can affect fertility in both women and men. This video covers how to work with a reproductive endocrinologist, the first steps after getting your diagnosis, what to consider before starting treatment, and options after completing treatment.
Lung Cancer Masterclass: Get Smart About Lung Cancer
Lung Cancer Masterclass: Get Smart About Lung Cancer
In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches have also become more effective and efficient. These options are fantastic steps toward improving the overall survival and quality of life for people living with lung cancer, but it can be difficult for patients and caregivers to keep track of the new drug treatments and scientific advancements. …
Finding Balance in Life and Treatment with Marnie Clark
Finding Balance in Life and Treatment with Marnie Clark
The symptoms that led Marnie Clark to her doctor were unusual. Her leg was feeling “weird,” but it was more of an annoyance than something she was concerned about. Then came an issue she couldn’t ignore—her leg was paralyzed, and she couldn’t move it. “The doctor thought it had to be something physically wrong with my leg, but over the previous two years I started to take my health seriously and was working with a personal trainer. I was feeling strong, so it didn’t make sense that I had a…
Questions to Ask About Clinical Trials
Questions to Ask About Clinical Trials
Asking your doctor and medical team questions about clinical trials is a helpful way to decide if they are a good fit for you. You may already have some in mind, but a few basic questions to ask and get answered before making a decision are:Do you know of any clinical trials for my type and stage of lung cancer?What are the benefits and risks of this clinical trial?What are the eligibility guidelines?How long does the study last?Will you still be in charge of my care?What are the costs, and…
Clinical Trial Phases
Clinical Trial Phases
The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes, this short video explains how researchers use clinical trials for new lung cancer treatments.Phases of a Clinical Trial:1. Safety of the new treatment 2. Does the cancer respond to the treatment 3. Is this new treatment better than the current options 4. Studies the long-term benefits and side effects
Helpful Apps for People Living with Cancer
Helpful Apps for People Living with Cancer
As mobile apps become more ingrained in our lives, it’s natural to look for ones that can help manage a cancer diagnosis. As for which app to choose, it really comes down to what you’re looking for, what you’re comfortable with, and what fits your needs. This list of helpful apps for people living with cancer includes ones that range from very basic, essentially a mobile pen and piece of paper, to all-in-one solutions that make medication tracking, document management, and…